Search
Boehringer_Ingelheim_Unternehmensbericht_2016.pdf
Boehringer_Ingelheim_Company_Profile_2017.pdf
Boehringer_Ingelheim_Consolidated_Companies_2016.pdf
FSA-Transparenzbericht Boehringer Ingelheim 2016.pdf
Media & News | Bioxcellence | Boehringer Ingelheim
Stay updated with BioXcellence Media & News. Explore the latest industry trends & news in global biopharmaceutical contract manufacturing. Don't miss out!
Partnering with Boehringer Ingelheim HP OCTOBER 2024 CORP.pdf
Transforming Science Day Europe
Oct. 2, 2023: Join us in London, or virtually, to learn more about our patient-centric approach to innovation, advancing pipeline and partnering approach.
biologicals-development-center
Europe’s largest biotechnology center in Biberach, Germany is the home to three development units.
Europe needs a vibrant research eco-system
At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
Resizing our Carbon Footprint
The ecological balance of the world is at a tipping point.
World-Psoriasis-Day-IFPA-Interview
Interview with the International Federation of Psoriasis Associations (IFPA)
How do our donations for Ukraine help?
The war in Ukraine continues to cause suffering and hardship. The Polish and the German Red Cross – also supported by donations from us – help to the best of their ability.
Drug Discovery Process
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance
AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
Tomorrow's leaders
We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Purpose Hero Video
Begin a career with purpose and explore careers at Boehringer Ingelheim.
Global mobility
We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.
New study paves the way for liver cirrhosis treatments
The ADVANCE study will be the most detailed observational study of its kind providing a detailed analysis of liver health.
Translational Medicine in Immunology
Find out how translational medicine is helping bring transformational therapies to patients
Results for Jardiance EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
What Our Partners Say
What Our Partners Say